Skip to main
VCYT

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte (VCYT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 71%
Buy 0%
Hold 14%
Sell 14%
Strong Sell 0%

Bulls say

Veracyte is a leader in the rapidly growing market for genomic diagnostics, with an expanding portfolio of advanced tests that improve patient outcomes and reduce costs. The recent results from the OPTIMA trial and the upcoming presentation at ASCO 2026 showcase the effectiveness of their Prosigna test in guiding chemotherapy decisions in breast cancer patients. With their strong revenue growth, favorable market conditions, and a promising pipeline of new tests, Veracyte has the potential for sustained long-term growth.

Bears say

Veracyte is well-positioned to capture meaningful market share in the evolving genomic diagnostics industry, with a solid portfolio consisting of its Decipher, Afirma, and Percepta tests. The company's upcoming entry into the MRD market for bladder cancer also presents potential growth opportunities. However, competition remains high in this industry, and Veracyte may experience challenges in gaining momentum with its kit-based strategy for expansion in Europe. With a current price target of $48, we believe that Veracyte's revenue growth of 12-16% may not meet investor expectations in the long term, limiting potential upside for the stock.

Veracyte (VCYT) has been analyzed by 7 analysts, with a consensus rating of Buy. 71% of analysts recommend a Strong Buy, 0% recommend Buy, 14% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veracyte (VCYT) Forecast

Analysts have given Veracyte (VCYT) a Buy based on their latest research and market trends.

According to 7 analysts, Veracyte (VCYT) has a Buy consensus rating as of Jun 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veracyte (VCYT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.